Akut mieloid leukémia (AML): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Therapeutic restoration of CUX1 in -7/del(7q) acute myeloid leukemia

  University of Chicago· Chicago, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 78 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R56

  Cooperation partners of SETBP1 in AML development

  Henry M. Jackson Fdn for the Adv Mil/Med· Bethesda, Egyesült Államok· 149 152 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R21

  Loss of TET2 Promotes Leukemogenesis by Enhancing NPY-Mediated PRC2 Disruption and CTCFL Chromatin Remodeling

  Indiana University Indianapolis· Indianapolis, Egyesült Államok· 407 543 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Svédország· EU contribution 2 000 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes (LIFE)

  Universitat Basel· Basel, Svájc· EU contribution 1 499 511 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Integrating DNA Methylation and Drug Abundance at Single-Cell Resolution to Predict Cancer Drug Sensitivity (EPI-SENSOR)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 1 499 423 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneity (PerturbPhos)

  Universitatsklinikum Jena· Jena, Németország· EU contribution 1 491 735 EUR· until 2031. szept.

  The disease is named only in the funder's project summary, not in the title.

10 of 499 running projects, newest first. Listed amounts together: 310,8 M USD + 53,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

  NCT03755414· Washington University School of Medicine· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 88
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 160
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Immunophenotyping of Acute Myeloid Leukemia.

  Methods Mol Biol, 2027. jan.

• Measurable Residual Disease.

  Methods Mol Biol, 2027. jan.

• Allogeneic hematopoietic stem cell transplantation is associated with improved long-term survival and molecular MRD clearance in KMT2A-altered AML.

  Ann Med, 2026. nov.

• ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia.

  Cancer Med, 2026. nov.

• Minor Myeloid Leukemic Populations in Pediatric Acute Lymphoblastic Leukemia: A Potentially Underrecognized Mixed-Phenotype Tumor?

  Int J Mol Sci, 2026. okt.

• Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

  Libyan J Med, 2026. szept.

• Flow Cytometric Detection of Intracellular Proteins in K562 Human Erythroleukemia Cells Using Unconjugated Primary Antibodies.

  J Vis Exp, 2026. szept.

• Pilot study on RECAF (Receptor for Alpha-Fetoprotein) expression in pediatric acute leukemia: insights from flow cytometry analysis.

  J Egypt Natl Canc Inst, 2026. szept.

• Ficoll-based isolation biases the profiling of immune cells and leukemic blasts in AML samples.

  Front Immunol, 2026. aug.

• Flow cytometric detection of isolated central nervous system relapse in acute myeloid leukemia under FLT3-targeted therapy.

  J Hematop, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.